« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 118, Issue 6
, Pages 1226-1233
, December 2006
Predicting episodes of poor asthma control in treated patients with asthma
References
- National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2002. Hyattsville (Md): Centers for Disease Control; 2003. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm. Accessed December 5, 2005.
- . Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95–100
- . National Asthma Education Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Institutes of Health; 1997;
- . Global initiative for asthma: global strategy for asthma management and prevention: NHLBI/VVHO workshop report. National Heart, Lung and Blood Institute publication #95-3659. Bethesda (MD): National Institutes of Health; 1995;
- . The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345:1529–1536
- . Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest. 1998;114:998–1007
- . Spirometric reference values from a sample of the general U. S. population. Am J Respir Crit Care Med. 1999;159:179–187
- Comparison of regularly scheduled with as-needed a use of albuterol in mild asthma. N Engl J Med. 1996;335:841–847
- Additive effects of inhaled formoterol and budesonide on reducing asthma exacerbations: a one-year controlled study. N Engl J Med. 1997;337:1405–1411
- Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583–2593
- . Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481–1488
- . Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids. Lancet. 1994;344:219–244
- The burden of asthma in the United States. Am J Respir Crit Care Med. 2002;166:1044–1049
- Worldwide severity and control of asthma in children and adults: the Global Asthma Insights and Reality surveys. J Allergy Clin Immunol. 2004;114:40–47
- . Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med. 2002;165:195–199
- Racial/ethnic variation in asthma status and management practices among children in managed Medicaid. Pediatrics. 2002;109:857–865
- . Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res. 2001;2:53–60
- . Prospective study of hospitalization for asthma: a preliminary risk factor model. Am J Respir Crit Care Med. 1995;151:647–655
- Exacerbations of asthma: a descriptive study of 425 severe exacerbation. Am J Respir Crit Care Med. 1999;160:594–599
- . Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med. 1998;157:123–128
- . Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57:226–230
- . Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168:1308–1311
- . Rates of admission to hospital for asthma. BMJ. 1994;308:1596–1600
- Agreement between measures of asthma status: a prospective study of low-income children with moderate to severe asthma. Pediatrics. 2002;110:797–804
- . Factors influencing parent reports on quality of life for children with asthma. J Asthma. 2003;40:577–587
Supported by the American Lung Association.Disclosure of potential conflict of interest: K. McCoy has received grant support from Chiron and Inspire Pharmaceuticals. C. G. Irvin has consulting arrangements with Biogen, MethaPharm, Merck, and Sepracor; has received grant support from GlaxoSmithKline; and is on the speakers' bureau for Merck. J. G. Mastronarde has received grant support from Pfizer and is on the speaker's bureau for GlaxoSmithKline. N. A. Hanania has received grant support from GlaxoSmithKline and Sepracor and is on the speakers' bureau for GlaxoSmithKline and Genentech. N. R. Anthonisen has served on advisory boards for GlaxoSmithKline and Altana and has received honoraria from GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(06)01906-3
doi: 10.1016/j.jaci.2006.09.006
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 118, Issue 6
, Pages 1226-1233
, December 2006
